Octagon Research Solutions, Inc. Launches Its New Viewpoint Quantum Web Site
Revolutionary site is foundation for industry’s first process management community
(WAYNE, PA, September 19, 2008) — CEO Chairman Jim Walker <http://www.octagonresearch.com/management-team.html> of Octagon Research Solutions, Inc. <http://www.octagonresearch.com/> , a pioneer and leading provider of breakthrough software and services to the life sciences industry, today announced the launch of its new website www.viewpointquantum.com <http://www.viewpointquantum.com/> . The new website provides information about Octagon’s ViewPoint Quantum platform, which will be released this Fall. The site uses social media such as Blogs and Discussion Forums to highlight and provide access to Octagon’s subject matter experts in electronic data, documents and submission lifecycles.
The ViewPoint Quantum platform builds on Octagon’s holistic, process-centric approach, providing the power and business intelligence to drive complex, global processes throughout the enterprise. The ViewPoint Quantum platform will also introduce the concept of Accelerated Publishing, Octagon’s vision of a proactive, process-aware and just-in-time approach for improving the regulatory submission process. The new website will present these concepts and encourage open discourse about other important industry topics including global submission management and process metrics.
The first Blogs featured on the site are, “Product Perspectives <http://www.viewpointquantum.com/community/> ,” authored by Dave Kettinger <http://www.viewpointquantum.com/quantum-bios.html> , senior director, Product Management and “Submission Sagas <http://www.viewpointquantum.com/community/> ,” authored by Leah Kleylein <http://www.viewpointquantum.com/quantum-bios.html> , principal consultant, Product Management. In Mr. Kettinger’s Blog, he will share his experiences and perspectives based on nearly 20 years leading custom and commercial software initiatives. In Ms. Kleylein’s Blog, she will share perspectives on the challenges and pitfalls of submission management based on her 16 years in the life sciences industry. She will also discuss current topics such as eCTD and the emerging RPS standard.
“We are pleased to announce the launch of the ViewPoint Quantum website,” noted Kathy Bouldin, senior manager, Marketing, Octagon Research Solutions, Inc. “We believe that the site will help us to develop a strong community using social media to bring visitors together who have common interests and experiences. We are encouraging our visitors to voice their opinions and share their knowledge."
“We have provided some initial content to get the ball rolling but we are hoping that our community of users will drive the discussion forums and blog topics,” noted Monique Garrett, vice president, Marketing. “For example, there are many of us in industry who have accumulated years of submission war stories and some of these stories are really entertaining. We are creating a space on the site where folks can submit their worst war stories and enter a contest. The winner of the submission war stories contest will receive a prize and have their story featured in an animated video on the ViewPoint Quantum website.”
www.viewpointquantum.com <http://www.viewpointquantum.com/> represents the first industry website to utilize social media to cover such a broad range of topics relating to process management. For more information about ViewPoint Quantum or to learn more about Octagon’s people, process and technology, please visit www.viewpointquantum.com <http://www.viewpointquantum.com/> .
About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading provider of breakthrough software and services to the life sciences industry. Octagon’s eCTD and CDISC solutions provide the people, process and technology required to optimize drug development from data collection to submission. Our regulatory, clinical, process and software offerings provide a unique combination of deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Berkhamsted, UK. Octagon’s EDC Operations are located in Mountain View, CA. For more information please visit www.octagonresearch.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
